NFASC and myeloid sarcoma: Neurofascin is also a target for autoantibodies, as demonstrated by the presence of neurofascin-specific autoantibodies in patients with MS [18], [19], Guillain-Barre syndrome [20], and chronic idiopathic demyelinating neuropathy [21], [22].